SPRY · Company research
ARS Pharmaceuticals, Inc. (SPRY): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits | SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| ARS Pharmaceuticals (SPRY) Short Interest & Short Float | Updated Oct 2026 $SPRY - MarketBeat | ARS Pharmaceuticals (SPRY) Short Interest & Short Float | Updated Oct 2026 $SPRY MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY | A securities class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly stated coverage would begin July 1, 2026, while concealing material adverse facts about the actual timeline, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY | A securities class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly stated coverage would begin July 1, 2026, while concealing material adverse facts about the actual timeline, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role | A class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product (neffy) with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to adequately disclose risks that the deadline might not be met, potentially impacting summer and back-to-school sales. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role | A class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product (neffy) with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to adequately disclose risks that the deadline might not be met, potentially impacting summer and back-to-school sales. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action - Contact SueWallSt - PR Newswire | SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action - Contact SueWallSt PR Newswire | View source ↗ | PR Newswire | Sep 24, 2026 | neutral | 0 | 0.6 |
| SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact Levi & Korsinsky - PR Newswire | SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Sep 23, 2026 | neutral | 0 | 0.6 |
| ARS Pharmaceuticals (NasdaqGM:SPRY) Stock Forecast & Analyst Predictions - Simply Wall Street | ARS Pharmaceuticals (NasdaqGM:SPRY) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 8, 2026 | neutral | 0 | 0.6 |
| ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share - Yahoo Finance | ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share Yahoo Finance | View source ↗ | Yahoo Finance | Aug 21, 2026 | neutral | 0 | 0.6 |
| ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen - Simply Wall Street | ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen Simply Wall Street | View source ↗ | Simply Wall Street | Aug 15, 2026 | neutral | 0 | 0.6 |
| ARS Pharmaceuticals' Needle-Free Epinephrine Spray Posts $26.2M in Q2 Sales - Stock Titan | ARS Pharmaceuticals' Needle-Free Epinephrine Spray Posts $26.2M in Q2 Sales Stock Titan | View source ↗ | Stock Titan | Aug 13, 2026 | neutral | 0 | 0.6 |
| ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance | ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 13, 2026 | neutral | 0 | 0.6 |
| ARS Pharmaceuticals CEO to outline updated priorities Aug. 13 - Stock Titan | ARS Pharmaceuticals CEO to outline updated priorities Aug. 13 Stock Titan | View source ↗ | Stock Titan | Aug 3, 2026 | neutral | 0 | 0.6 |
| ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky - PR Newswire | ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Jul 6, 2026 | neutral | 0 | 0.6 |
| ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices - Yahoo Finance | ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices Yahoo Finance | View source ↗ | Yahoo Finance | Jun 28, 2026 | neutral | 0 | 0.6 |
| SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - Stocktwits | SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today Stocktwits | View source ↗ | Stocktwits | Jun 24, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.